{"id":"atrasentan-high-dose-group","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Edema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking endothelin-1, atrasentan reduces vascular resistance and lowers blood pressure. This mechanism is particularly relevant in the treatment of hypertension and related cardiovascular conditions.","oneSentence":"Atrasentan is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:34.395Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT01424319","phase":"PHASE2","title":"Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-08","conditions":"Chronic Kidney Disease, Diabetic Nephropathy","enrollment":58},{"nctId":"NCT01399580","phase":"PHASE2","title":"A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-08","conditions":"Chronic Kidney Disease, Diabetic Nephropathy","enrollment":48},{"nctId":"NCT01356849","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-04","conditions":"Chronic Kidney Disease, Diabetic Nephropathy","enrollment":149}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Atrasentan high dose group","genericName":"Atrasentan high dose group","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atrasentan is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}